SCHEMBL208749

SCHEMBL208749

CN(C)C1(c2cccs2)CCC(NC(=O)CCC(=O)N2CCC(O)(c3cccc(C(F)(F)F)c3)CC2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 6/20 0.45
KCNH2 Q12809 5/20 0.45
OPRL1 P41146 8/20 0.44
OPRM1 P35372 7/20 0.44
CHRM4 P08173 1/20 0.43
OPRK1 P41145 3/20 0.42
ABCB11 O95342 1/20 0.41
TP53 P04637 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
PKM P14618 1/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
THPO P40225 1/20 0.41
MTOR P42345 1/20 0.41
EBP Q15125 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PMP22 Q01453 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084332 0.92 OPRM1 (0.43) CCR2KCNH2OPRL1OPRM1
SCHEMBL206307 0.90 OPRM1 (0.52) CCR2KCNH2OPRL1OPRM1CHRM4
SCHEMBL5158003 0.86 CHRM4 (0.42) CCR2KCNH2OPRL1OPRM1CHRM4
SCHEMBL5157641 0.81 OPRM1 (0.43) CCR2KCNH2OPRL1OPRM1CHRM4
SCHEMBL207647 0.79 KDM4E (0.46) KDM4ESMN1; SMN2
SCHEMBL208760 0.78 SMYD3 (0.48) CCR2KCNH2OPRL1OPRM1SIGMAR1
SCHEMBL206822 0.75 OPRM1 (0.47) OPRL1OPRM1SMN1; SMN2
SCHEMBL206198 0.73 ALDH1A1 (0.45) SMN1; SMN2
SCHEMBL4074077 0.73 OPRM1 (0.51) OPRL1OPRM1SMN1; SMN2
SCHEMBL206119 0.73 OPRM1 (0.43) CCR2KCNH2OPRL1OPRM1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US claimed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP claimed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US claimed
US-8088763-B2 e.g. N-[1-(2,6-dichloro-benzyl)-pyrrolidin-3-yl]-N'-[4-dimethylamino-4-(4-methyl-benzyl)-cyclohexyl]-succinamide; noradrenaline and serotonin reuptake ihibitor; opioid ORL-1 receptor ligand; analgesic, antidepressant, anxiolytic agent, neurodegenerative diseases GRUENENTHAL GMBH (DE) 2012-01-03 US disclosed
EP-1745010-B1 SUBSTITUTED CYCLOHEXYL-1,4-DIAMINE DERIVATIVES GRUENENTHAL GMBH (DE) 2009-08-05 EP disclosed
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds GRUENENTHAL GMBH (DE) 2007-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112007-A1 Cyclohexyl-1, 4-diamine compounds PKD1, DDC, DPYD CCR2 2965/4885KCNH2 3000/4885OPRL1 2751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.